SCHEMBL2981986

SCHEMBL2981986

O=C(O)c1ccc(OCCOC2CCCCO2)cc1

nearest known ligand 0.88

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.88
KMT2A Q03164 1/20 0.88
PKM P14618 1/20 0.51
TP53 P04637 1/20 0.47
TSHR P16473 1/20 0.47
PLA2G4B P0C869 1/20 0.46
RARB P10826 4/20 0.45
KDM4C Q9H3R0 1/20 0.44
HTT P42858 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAPK1 P28482 1/20 0.43
CREBBP Q92793 1/20 0.43
ALDH1A1 P00352 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1531929 0.94 MEN1 (1.00) MEN1KMT2APKMTP53TSHR
SCHEMBL9335079 0.94 MEN1 (0.95) MEN1KMT2APKMTP53TSHR
SCHEMBL224651 0.94 MEN1 (1.00) MEN1KMT2APKMTP53TSHR
SCHEMBL224471 0.94 MEN1 (1.00) MEN1KMT2APKMTP53TSHR
SCHEMBL1813642 0.91 MEN1 (0.73) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL28597015 0.90 MEN1 (0.93) MEN1KMT2APKMTP53TSHR
SCHEMBL7338905 0.90 MEN1 (0.93) MEN1KMT2APKMTP53TSHR
SCHEMBL1930907 0.88 MEN1 (0.70) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL22089857 0.87 MEN1 (0.87) MEN1KMT2ATP53TSHRPLA2G4B
SCHEMBL14281436 0.87 KMT2A (0.67) MEN1KMT2AKDM4CNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7777041-B2 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof SANOFI-AVENTIS (FR) 2010-08-17 US disclosed
US-20090156574-A1 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-06-18 US disclosed
US-7504511-B2 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof SANOFI-AVENTIS (FR) 2009-03-17 US disclosed
US-20060135575-A1 2-Acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof SANOFI-AVENTIS (FR) 2006-06-22 US disclosed
EP-1656373-A2 DERIVATIVES OF 2-ACYLAMINO-4-PHENYLTHIAZOLE, PREPARATION METHOD THEREOF AND USE OF SAME AS CHEMOKINEANTAGONISTS Sanofi-Aventis (FR) 2006-05-17 EP disclosed
WO-2004096798-A2 DERIVATIVES OF 2-ACYLAMINO-4-PHENYLTHIAZOLE, PREPARATION METHOD THEREOF AND USE OF SAME AS CHEMOKINE ANTAGONISTS SANOFI-AVENTIS (FR) 2004-11-11 WO disclosed
US-4359424-A Substituted phenoxyethoxytetrahydropyran ZOECON CORPORATION (US) 1982-11-16 US disclosed
US-4304924-A Cyclopropylmethyl benzoates ZOECON CORPORATION (US) 1981-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135575-A1 2-Acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof PAH, ABAT, AADAT MEN1 3039/4885KMT2A 901/4885PKM 314/4885
US-20090156574-A1 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF PAH, ABAT, AADAT MEN1 3039/4885KMT2A 901/4885PKM 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.